Open an account

Zentalis Pharmaceuticals

ZNTL · NASDAQ

$2.39+$0.09 (+3.91%)TodayMarket closed ·
Prev close $2.30

About ZNTL

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in San Diego, California and currently employs 106 full-time employees. The company went IPO on 2020-04-03. The firm is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The firm is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.

Employees
106
Headquarters
San Diego, California
Listed
Apr 3, 2020
Sector
Health Care
Industry
Biotechnology
Website
zentalis.com

ZNTL key statistics

Market cap
350.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.44M
Volume
1.56M
Open price
$2.31
High today
$2.44
Low today
$2.25
52 Week high
$6.95
52 Week low
$1.21

Zentalis Pharmaceuticals (ZNTL) at a glance

As of Oct 20, 2026, Zentalis Pharmaceuticals (ZNTL) shares are priced at $2.39, giving the company a market cap of 350.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.25 and $2.44. The current price is 6.2% above the day's low and 2.0% below its high.

Volume so far is 1.56M shares, in line with the average of 1.44M shares a day.

Over the past year Zentalis Pharmaceuticals has ranged from $1.21 to $6.95, and now sits 21% of the way up that range.

Zentalis Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.59 per share against an estimate of -$0.4997.

ZNTL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 25.3% on average.

  1. Q3 FY24: reported -$0.56 per share against an estimate of -$0.9282
  2. Q4 FY24: reported -$0.62 per share against an estimate of -$0.7199
  3. Q1 FY25: reported -$0.56 per share against an estimate of -$0.6505
  4. Q2 FY25: reported -$0.37 per share against an estimate of -$0.593
  5. Q3 FY25: reported -$0.37 per share against an estimate of -$0.5384
  6. Q4 FY25: reported -$0.50 per share against an estimate of -$0.5906
  7. Q1 FY26: reported -$0.50 per share against an estimate of -$0.4861
  8. Q2 FY26: reported -$0.59 per share against an estimate of -$0.4997

ZNTL news

  • Vandana Singh

    This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Avi Kapoor

    Nasdaq Moves Higher; US Inflation Rate Accelerates In March

  • Alex Perry

    What's Behind The Surge In Zentalis Stock?

  • Press releasePRNewswire

    Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Similar companies

Companies in the same industry as Zentalis Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.